Information letter to health care professionals regarding the safe use of the medicinal product MERIGEN (drospirenone/ethinylestradiol). Risk of venous and arterial thromboembolism with the use of combined hormonal contraceptives

19.01.2026 464 views

Інформаційний лист-звернення до спеціалістів системи охорони здоров’я щодо безпеки застосування лікарського засобу МЕРІЖЕН (дроспіренон/етинілестрадіол). Ризик виникнення венозних та артеріальних тромбоемболій при застосуванні комбінованих гормональних контрацептивівPDF · 268 КБ

Завантажити

Information letter to health care professionals regarding the safe use of the medicinal product MERIGEN (drospirenone/ethinylestradiol). Risk of venous and arterial thromboembolism with the use of combined hormonal contraceptives

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration

Information letter to health care professionals regarding the safe use of the medicinal product MERIGEN (drospirenone/ethinylestradiol). Risk of venous and arterial thromboembolism with the use of combined hormonal contraceptives

Other materials in this section

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration